KH
Public post
Katherine Harris
Sep 2026 • linkedin
Post excerpt
AbbVie announced positive Phase 3 results today for etentamig (ABBV-383) in relapsed/refractory multiple myeloma. A 74% objective response rate versus 46% for standard therapies. Among patients on the single step-up dose, CRS was predominantly grade 1 with no grade 3 or higher events. Dosing is once monthly from initiation, which opens the door to treating patients in outpatient and community settings rather than only at specialist centers. This molecule began as TNB-383B at TeneoBio, where I was part of the team …
Find the people and context behind this post
Sign up for Super Carl to explore relationship context, warm paths, and relevant opportunities.